LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Clinical-stage pharma company developing PP2A inhibitors to enhance cancer therapies.
LIXT | US
Overview
Corporate Details
- ISIN(s):
- US5393191110 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 433 PLAZA REAL, 33432 BOCA RATON
- Website:
- https://lixte.com/
Description
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapies called Protein Phosphatase 2A (PP2A) inhibitors. The company's lead compound, LB-100, is a first-in-class molecule designed to enhance the efficacy of existing treatments, including chemotherapy and immunotherapy. By inhibiting the PP2A enzyme, a critical regulator of cellular functions, LB-100 aims to overcome treatment resistance in cancer cells. This approach seeks to improve outcomes for a broader range of patients by increasing the effectiveness of standard oncology therapies. The compound has demonstrated synergy with both chemotherapy and immunotherapy in pre-clinical models.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all LIXTE BIOTECHNOLOGY HOLDINGS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for LIXTE BIOTECHNOLOGY HOLDINGS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for LIXTE BIOTECHNOLOGY HOLDINGS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
